GTG 0.00% 4.4¢ genetic technologies limited

New England Journal of Medicine (B+)

  1. 3,077 Posts.
    lightbulb Created with Sketch. 46
    2:41 pm Genetic Technologies subsidiary Phenogen Sciences highlights a report in the The New England Journal of Medicine that may regard its BrevaGenplus test (GENE) : According to The New England Journal of Medicine article, there is a reasonably clear distinction between single nucleotide polymorphisms that confer a small increased susceptibility to breast cancer and variants that confer a moderate-to-high susceptibility as identified through sequencing.

    BREVAGenplus evaluates a panel of SNPs known to be associated with sporadic breast cancer combined with clinical risk factors to provide a more accurate risk assessment.
    .
 
watchlist Created with Sketch. Add GTG (ASX) to my watchlist
(20min delay)
Last
4.4¢
Change
0.000(0.00%)
Mkt cap ! $6.398M
Open High Low Value Volume
4.4¢ 4.5¢ 4.1¢ $20.25K 465.6K

Buyers (Bids)

No. Vol. Price($)
1 10443 4.4¢
 

Sellers (Offers)

Price($) Vol. No.
4.5¢ 27478 1
View Market Depth
Last trade - 15.06pm 26/07/2024 (20 minute delay) ?
GTG (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.